NICE update doubles eligible patients for AZ's Lokelma AstraZeneca's hyperkalaemia drug Lokelma could see its use by the NHS more than double thanks to updated guidance from NICE.

#NICE #AZ #Lokelma #nephrology #AstraZeneca #hyperkalaemia #NHS #NICEcosteffectivenessthreshold #realworldevidence #reimbursement #NICEdraftguidance #persistenthyperkalaemia #chronickidneydisease #CKD #heartfailure #RAASinhibitors #RAASinhibitortherapies #TomKeithRoach #RWEdata
zurl.co/nl7Fy